Lipp R, Laurent H, Günther C, Riedl J, Esperling P, Täuber U
Research Laboratories of Schering AG, Berlin, Germany.
Pharm Res. 1998 Sep;15(9):1419-24. doi: 10.1023/a:1011957822961.
The aim of this study was to enhance the transdermal absorption of the highly active progestin gestodene from matrix type transdermal delivery systems (TDDS) by formation of prodrugs with improved matrix solubility.
Gestodene esters were synthesized via acylation of the drug with the respective carboxylic anhydrides. Subsequently TDDS were produced using the solvent cast method. Selected formulations were examined with in vitro diffusion experiments using skin of nude mice.
One prodrug, gestodene caproate proved to be an oil at ambient temperature and showed a very high solubilty of over 10.5% in the TDDS matrix. Within in vitro penetration studies using those systems the prodrug exhibited a significantly higher transdermal penetration rate than gestodene from reference systems. Furthermore, the prodrug was hydrolyzed to the parent drug to a high extent during the passage of the skin.
Designing prodrugs to the requirements of matrix TDDS is an efficient way of enhancing the transdermal drug flux rate.
本研究旨在通过形成具有改善的基质溶解性的前药,提高高活性孕激素孕二烯酮从基质型透皮给药系统(TDDS)的透皮吸收。
通过用相应的羧酸酐对药物进行酰化反应合成孕二烯酮酯。随后采用溶剂浇铸法制备TDDS。使用裸鼠皮肤进行体外扩散实验,对选定的制剂进行检测。
一种前药,己酸孕二烯酮在常温下为油状,在TDDS基质中的溶解度非常高,超过10.5%。在使用这些系统的体外渗透研究中,该前药的透皮渗透速率明显高于参比系统中的孕二烯酮。此外,该前药在透过皮肤的过程中会大量水解为母体药物。
根据基质TDDS的要求设计前药是提高透皮药物通量率的有效方法。